BioHarvest Sciences (BHST) Stock Price, News & Analysis

Company Overview

BioHarvest Sciences Inc is a biotechnology company specializing in the development and commercialization of plant cell-derived bioactives for the natural health, skincare and aesthetic medicine markets. Using its proprietary BioFarming platform, the company cultivates pure plant cells in bioreactors to produce high-potency botanical extracts. These extracts are designed to deliver enhanced antioxidant, anti-inflammatory and regenerative properties without the variability often associated with traditional agriculture.

The company’s product portfolio spans nutraceutical ingredients, topical cosmeceutical formulations and injectable aesthetic compounds. By controlling the entire cultivation process—from cell selection through harvest—BioHarvest Sciences can tailor molecular profiles to meet specific performance benchmarks. Its ingredients are incorporated by contract manufacturers, dermatological clinics and consumer brands seeking clinically validated, sustainable alternatives to conventional botanicals.

Founded in 2013 in Israel and later establishing its corporate headquarters in Hempstead, New York, BioHarvest Sciences has aligned its research and production capabilities across North America, Europe and Asia. The company completed its initial public offering on the Nasdaq in 2021, opening access to U.S. capital markets to accelerate product development and global market entry. Its R&D operations remain centered in Tel Aviv, where ongoing research explores new plant species and applications in wellness and aesthetics.

Leadership at BioHarvest Sciences is headed by Chief Executive Officer David J. McIntosh, whose background spans biotechnology licensing and strategic partnerships. The executive team includes seasoned professionals in pharmaceutical development, consumer product marketing and industrial manufacturing. Guided by an independent board of directors with extensive life-sciences experience, the company continues to expand its pipeline of patented cell-based extracts and forge collaborations across multiple end-markets.

Key Stats

• Today's Range: $6.93 to $7.25
• 50-Day Range: $6.10 to $7.66
• 52-Week Range: $4.66 to $7.86
• Volume: 5,226 shs
• Average Volume: 7,174 shs
• Market Capitalization: $117.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.67
• Consensus Rating: Buy

BHST Stock Analysis - Frequently Asked Questions

How have BHST shares performed this year?

BioHarvest Sciences' stock was trading at $6.18 at the beginning of 2025. Since then, BHST shares have increased by 16.2% and is now trading at $7.18.

How were BioHarvest Sciences' earnings last quarter?

BioHarvest Sciences Inc. (NASDAQ:BHST) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. The firm had revenue of $7.64 million for the quarter, compared to the consensus estimate of $8.93 million. BioHarvest Sciences had a negative net margin of 31.30% and a negative trailing twelve-month return on equity of 307.04%.
Read the conference call transcript.

How do I buy shares of BioHarvest Sciences?

Shares of BHST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BHST
• Previous Symbol: NASDAQ:BHST
• CIK: 1723464
• Web: bioharvest.com
• Phone: 646-863-2177
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioHarvest Sciences: $13.67
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +90.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.91 million
• Net Margins: -31.30%
• Pretax Margin: -31.13%
• Return on Equity: -307.04%
• Return on Assets: -33.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.51
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 4.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 89.75

Miscellaneous

• Outstanding Shares: 16,420,000
• Free Float: N/A
• Market Cap: $117.90 million
• Optionable: N/A
• Beta: 0.65